The purpose of this observational study is to collect and evaluate real-world data to assess the effectiveness of neoadjuvant nivolumab when given in combination with platinum-based chemotherapy in participants with early-stage, resectable non-small cell lung cancer (NSCLC) in Germany
Aged 18 years or older
Diagnosis of non-metastatic non-small cell lung cancer with tumor Programmed death-ligand 1 (PD-L1) expression level of 1% or more (tumor proportion score (TPS); according to label approved in the European Union)
Decision to initiate a neoadjuvant treatment with nivolumab plus platinum-based chemotherapy for treatment of non-small cell lung cancer according to current Summary of product characteristics and independent of the study
Willing to complete patient-reported outcome questionnaires and sufficient understanding of the German language
Current primary diagnosis of cancer other than non-small cell lung cancer that requires systemic or other treatment
Other contraindications according to current Summary of product characteristics
Adult participants aged ≥ 18 years of age or older who are diagnosed with resectable non-small cell lung cancer at high risk of recurrence and whose tumors have programmed death-ligand 1 (PD-L1) expression ≥ 1%
Cohort
Prospective
Neoadjuvant nivolumab in combination with platinum-based chemotherapy
DrugNeoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics
Event-free survival
Pathologic complete response (pCR) rate
Rate of major pathologic response (MPR)
Rate of partial pathologic response (pPR)
Rate of pathologic non-responder
Click on the lead sponsor to view all of their trials.
